Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07183319 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Circulating Tumor DNA Response In Urothelial Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date changed from estimate of Dec 2025 to Jan 19, 2026v4
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Oct 2025 to Dec 2025
    • Site details revised
    v3
  3. Start date: Sep 2026 to Oct 2025
    • Interventions: De-escalation Phase (Drug), Rechallenge (Drug), Standard Dose (PEV) (Drug) to Pembrolizumab & Enfortumab Vedotin (PEV) (Drug), Pembrolizumab & Enfortumab Vedotin (PEV) (Drug), Pembrolizumab (Drug)
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this clinical trial is to evaluate the effectiveness of pembrolizumab monotherapy following 24 weeks of frontline pembrolizumab \& Enfortumab Vedotin (PEV) in patients with metastatic urothelial cancer (mUC).
Trial Details
NCT Number NCT07183319
Lead Sponsor University of Oklahoma
Collaborators: Natera, Inc.
Conditions
(from sponsor)		 Urothelial Carcinoma
Related terms Carcinoma, Transitional Cell, Neoplasm Metastasis
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov